减肥药巨头的大手笔收购让成纤维细胞生长因子21（FGF21）再次受到行业关注。 当地时间10月9日，丹麦药企诺和诺德宣布，公司已与Akero Therapeutics达成最终协议，将以每股54美元的现金价格收购后者普通股的所有流通股，总价值47亿美元。此外，Akero Therapeutics股东将获得不可转让的或有价值权（CVR），在美国监管部门批准在研产品Efruxifermin用于治疗...
Source Link减肥药巨头的大手笔收购让成纤维细胞生长因子21（FGF21）再次受到行业关注。 当地时间10月9日，丹麦药企诺和诺德宣布，公司已与Akero Therapeutics达成最终协议，将以每股54美元的现金价格收购后者普通股的所有流通股，总价值47亿美元。此外，Akero Therapeutics股东将获得不可转让的或有价值权（CVR），在美国监管部门批准在研产品Efruxifermin用于治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.